MedTrace Logo

Safety and Effectiveness of the PXL-Platinum 330 System for Cornea Crosslinking in Eyes With Cornea Thinning

NCT05516004 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2024-06-14

No results posted yet for this study

Summary

This study study is to determine the effectiveness of cornea cross linking in patients with Keratoconus or other cornea thinning conditions.

Conditions

  • Keratoconus

Interventions

DEVICE

PXL Platinum 330 system

to determine the efficacy of riboflavin solution and UV light to treat cornea thinning conditions

Sponsors & Collaborators

  • Cohen Laser and Vision Center

    lead OTHER

Principal Investigators

  • Kelly Fitzgerald · WCG IRB

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-01
Primary Completion
2034-06-01
Completion
2034-06-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05516004 on ClinicalTrials.gov